ZyrTEC-D

Method of action: Antitussive, Nasal Preparations

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of ZyrTEC-D

What is ZyrTEC-D? Definition and Classification

Property	Description
Active ingredient	Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride
Form	Extended-Release Tablet
Pharmacological class	Antihistamine and Nasal Decongestant Combination
Common use	Relief from upper respiratory allergy and congestion symptoms
Origin	Synthetic

ZyrTEC-D is defined as a Fixed-Dose Combination Product, classified as an Upper Respiratory Combination medicine. This specific formulation is clinically recognized for its efficacy in managing the dual discomfort of allergies and nasal congestion simultaneously, a key differentiating feature from single-ingredient allergy relievers.

Active Components and Delivery Form

The product's composition is based on two primary active ingredients: Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride. Cetirizine Hydrochloride is a selective Second-Generation Histamine H1 Antagonist. Pseudoephedrine Hydrochloride is classified as a Sympathomimetic Amine, which provides its decongestant action by targeting vascular swelling. The inclusion of Pseudoephedrine provides nasal decongestion through its vasoconstrictive properties.

The medicine is supplied as an Extended-Release Tablet, frequently utilizing a Bilayer Tablet design for oral administration. This formulation is engineered for sustained drug delivery, which is a recognized pharmaceutical mechanism for ensuring the beneficial effects of both the antihistamine and the decongestant are consistently maintained over a prolonged duration, distinguishing it from immediate-release formulations.

General Purpose and Dual-Action Benefit

The general therapeutic purpose of ZyrTEC-D is to offer comprehensive symptomatic management by targeting both the underlying allergic response and the physical manifestation of nasal swelling. The Cetirizine component works by blocking histamine effects, preventing the typical allergic reactions. Concurrently, the Pseudoephedrine component, by acting as a vasoconstrictor, reduces swelling and helps alleviate congestion. This dual-action benefit is particularly useful for individuals experiencing allergy symptoms that are compounded by a blocked nose.

What side effects are possible with ZyrTEC-D?

Possible Side Effects and Safety Information

The safety profile of ZyrTEC-D, a fixed-dose combination of an antihistamine (Cetirizine) and a decongestant (Pseudoephedrine), is defined by reactions documented in clinical trials and post-market surveillance as classified by regulatory authorities.

Adverse Reaction Classification

Side effects are officially classified by frequency and system. Common adverse reactions reported in regulatory documentation typically involve the Nervous System (e.g., drowsiness, headache, dizziness, insomnia) and Gastrointestinal Disorders (e.g., dry mouth, nausea, constipation, stomach pain). The frequency classification for these effects is documented as Common.

Serious Adverse Reactions and Safety Constraints

The official label lists potentially serious adverse reactions that require attention. These primarily include effects on the Cardiovascular System, such as severe hypertension (high blood pressure) and tachycardia (fast or pounding heartbeat), as well as CNS effects like seizures or severe stimulation. Serious allergic reactions are also officially noted.

Regulatory documentation formally lists several Contraindications (safety restrictions). The product is restricted in individuals with severe high blood pressure, severe coronary artery disease, narrow-angle glaucoma, and the inability to urinate (urinary retention). It is also strictly contraindicated for use with or within 14 days of stopping a Monoamine Oxidase Inhibitor (MAOI).

Population-Specific Safety

Official safety notes address specific populations. Older adults may be more susceptible to experiencing side effects. Dosage adjustments or caution are necessary for patients with documented renal (kidney) or hepatic (liver) impairment, as these conditions can alter how the body processes the medication's components. A specific, rare post-marketing observation noted the development of severe itching (pruritus) upon the discontinuation of long-term daily use of the cetirizine component.

Overdose and Emergency Response

Overdose of ZyrTEC-D is officially documented by regulatory sources to present with a range of central nervous system (CNS) manifestations. The presentation can be biphasic, reflecting the properties of its two active ingredients. Documented CNS excitation symptoms include agitation, restlessness, anxiety, and nervousness. CNS depression is characterized by severe drowsiness, somnolence, and confusion. Specific manifestations such as sleeplessness, hallucinations, and fixed/dilated pupils have also been noted in official reports of high-dose exposure.

Serious systemic outcomes documented in the labeling require urgent intervention. These include cardiovascular disturbances such as a fast or irregular heartbeat (tachycardia) and the potential for convulsions (seizures).

For any suspected overdose, official guidance from regulatory bodies mandates immediate emergency action. Individuals must get medical help or contact a Poison Control Center right away as stated in the prescribing information. Management is restricted to supportive and symptomatic treatment only. Regulatory documents clarify that no known specific antidote exists for the medicine, and the cetirizine component cannot be effectively removed by dialysis. Population-specific notes indicate that pediatric cases often resolve spontaneously, though children may display an initial phase of irritability followed by drowsiness.

Therapeutic Uses of ZyrTEC-D

What Zyrtec-D Treats: Main Uses and Benefits

Zyrtec-D is commonly used across conditions presenting with acute episodes of upper respiratory allergies like hay fever. The formulation is applied in addressing symptom clusters that may become intense or disruptive and interfere with daily functioning. This combination is generally applied in addressing the symptoms associated with acute or episodic changes.

The medication helps manage classic allergic manifestations, specifically including sneezing, itchy eyes, watery eyes, runny nose, and itching of the nose or throat. Furthermore, the decongestant component plays a role in managing symptoms related to noticeable physiological strain in the nasal passages. This action contributes to easing sinus congestion and pressure and assists with maintaining functional stability for freer breathing. This comprehensive approach supports the patient during phases of increased distress or discomfort by easing the overall symptom burden. This medicine is relevant when supportive symptom management is appropriate.

Quick Fact: Supports Management of symptoms related to physical discomfort

Regulatory References

NIH DailyMed drug label

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Official regulatory documents define strict eligibility criteria for the use of ZyrTEC-D. The medicine is approved for use in adults and adolescents 12 years of age and older.

Use is contraindicated (must not be used) in several population groups due to the components, primarily Pseudoephedrine:

Patients with known hypersensitivity to cetirizine, pseudoephedrine, hydroxyzine, or excipients.
Patients with severe hypertension (high blood pressure) or severe ischemic heart disease.
Patients taking or who have stopped a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.
Patients with severe renal insufficiency (kidney failure).

Restricted and Conditional Use

Use is not recommended in children under 12 years of age as safety and efficacy have not been established. Use is also not recommended during pregnancy and lactation (breastfeeding).

Specific conditions require patients to ask a doctor before use:

Organ Function: Moderate hepatic (liver) or moderate renal (kidney) impairment.
Age: Adults 65 years and over.
Comorbidities: Pre-existing conditions such as heart disease, diabetes, thyroid disease, glaucoma, or trouble urinating due to an enlarged prostate.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific restrictions and documented interaction patterns for ZyrTEC-D, which contains the active ingredients cetirizine and pseudoephedrine.

Contraindications and Separation Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated. The medicine must not be used if MAOI therapy has been discontinued within the preceding 14 days, as noted in the regulatory labeling.

Pharmacodynamic and Pharmacokinetic Interactions

Co-use with alcohol or other Central Nervous System (CNS) depressants (such as sedatives or tranquilizers) is documented to result in an additive depressant effect. This pharmacodynamic interaction may increase drowsiness and impairment.

Regarding pharmacokinetic alterations, the co-administration of Theophylline (at 400 mg once daily) is officially documented to cause a 16% decrease in the systemic clearance of cetirizine. Regulatory studies have also specifically noted no significant pharmacokinetic interaction with substances like Erythromycin, Ketoconazole, or Azithromycin.

Other Interaction Considerations

The extent of cetirizine absorption is not reduced by food, although the rate of absorption may be slowed. Furthermore, official documentation states that the clearance (elimination) of both active components is reduced in patients with renal impairment, which is a labeled consideration for accumulation risk.

Mechanism of Action

The physiological effect profile of ZyrTEC-D is defined by the complementary actions of its two components on distinct biological targets and pathways. One component functions as a Histamine-1 (H1) receptor antagonist, binding to H1 receptors and interrupting the chemical signaling initiated by the natural mediator, histamine. This mechanism suppresses the histamine-driven increase in capillary permeability, which is the key physiological process for the extravasation of fluid into local tissues.

Simultaneously, the second component acts as an indirect alpha-adrenergic agonist, primarily by promoting the release and activity of norepinephrine on alpha1-adrenergic receptors located on the walls of small blood vessels. The resulting alpha1-receptor activation causes the muscular walls of arterioles and venules to contract, inducing vasoconstriction. This physiological response leads to a reduction in local blood flow and volume in the microcirculation. The synergy between the H1-receptor blockade and the alpha-adrenergic modulation of vascular tone contributes to the overall physiological effect profile.

Dosage and Administration Information

How ZyrTEC-D is Used: Official Administration Guidelines

The administration of ZyrTEC-D is based on specific protocols designed to ensure the proper delivery of its fixed-dose combination. These protocols detail the standard administration route, dosing regimen, and required procedural constraints.

Administration Protocol

Instruction Domain	Official Protocol Detail
Route of Administration	The medicine is approved for oral use only.
Standard Dosing Regimen	The standardized dose for adults and children 12 years of age and older is one (1) Extended-Release Tablet.
Dosing Frequency and Limits	The schedule is a fixed twice-daily pattern, with a dose taken every 12 hours. The maximum intake is restricted to two (2) tablets within a 24-hour period.
Administration Conditions	The tablet may be administered with or without food. To maintain the integrity of the extended-release components, the tablet must be swallowed whole and must not be crushed or chewed.

Regulatory Context and Use Patterns

The framework for using ZyrTEC-D is established for short-term, episodic management. Usage is typically discontinued and professional medical guidance sought if symptoms are not relieved or do not improve within 7 days.

Furthermore, consultation with a physician is required for specific user groups before administration. This includes children under 12 years of age, adults 65 years and older, and individuals with pre-existing kidney or liver disease, as the determination of the appropriate usage pattern for these populations requires professional assessment.

This protocol outlines the fixed dose and timing required to match the pharmacological design of the combination product, ensuring a consistent approach to its use.

Recent Clinical Evidence

Evidence for Use in Allergic Rhinitis with Nasal Congestion

The research base for ZyrTEC-D includes randomized, double-blind, placebo-controlled crossover trials (RCTs), which are foundational for regulatory evaluation. This research was studied for individuals experiencing conditions characterized by fluctuating or episodic manifestations of upper respiratory allergies, including seasonal and perennial rhinitis, where nasal blockage is a significant issue.

The studies was evaluated in trials where subjects reported on their symptoms using scales like the Total Nasal Symptom Score (TNSS). Researchers examined whether there was a measured difference in these symptom parameters compared to placebo. The outcomes reported were short-term and based on the measured intensity of both nasal congestion and non-nasal symptoms. This evidence contributes to understanding symptom patterns during periods of heightened symptom activity, but the efficacy research primarily focused on short-term symptom changes.

Research on the Extended-Release Formulation and Drug Delivery

Technical research was studied for the specific design of the extended-release tablet to evaluate whether it delivers the active ingredients over time. These bioavailability and bioequivalence studies examined Pharmacokinetic (PK) parameters, such as the maximum concentration in plasma (Cmax). The research describes the sustained release mechanism and reports the resulting systemic exposure over a longer duration. This provides context on the drug's technical profile but does not directly measure or predict how an individual's symptoms will respond.

Study Duration and Evidence Gaps

The initial regulatory studies typically were observed in short-term research scenarios, with follow-up durations were limited to about one week. Consequently, long-term effects are not fully established regarding the durability of symptom change. Data for certain groups remain insufficient, particularly in older adults (aged 65 and older) or in children under 12, as the primary efficacy research focused on Adults and Adolescents aged 12 years and older. Furthermore, technical research relies on PK surrogate markers, meaning the information is limited regarding how these findings translate into clinical outcomes related to physical discomfort over extended periods.

Frequently Asked Questions (FAQ)

Common questions about ZyrTEC-D (FAQ)

Q: What is ZyrTEC-D used for?

A: ZyrTEC-D is indicated for the relief of symptoms associated with seasonal or perennial allergic rhinitis (hay fever) when both an antihistamine and a nasal decongestant are necessary. According to the official product information, this includes symptoms like nasal congestion, sneezing, runny nose, and itchy, watery eyes. It is designed to treat both the allergy symptoms and the blocked nose.

Q: How does ZyrTEC-D work?

A: ZyrTEC-D works because it contains two active ingredients: cetirizine and pseudoephedrine. Cetirizine is an antihistamine that helps block histamine, a substance the body releases during an allergic reaction, reducing symptoms like sneezing and itching. Pseudoephedrine is a decongestant that helps narrow blood vessels in the nasal passages, which reduces swelling and makes breathing easier. The combination of these two actions provides relief from both allergy and congestion symptoms.

Q: Can ZyrTEC-D be used for colds or flu?

A: Regulatory documents state that ZyrTEC-D is specifically indicated for symptoms associated with allergic rhinitis (allergies) and not for the common cold or flu. While it contains a decongestant that might temporarily help with congestion from a cold, its main purpose is to treat the symptoms caused by allergies. Use should align with the official indications for allergic symptoms that require both an antihistamine and a decongestant.

Q: Can ZyrTEC-D make you drowsy?

A: The official product information mentions that somnolence (drowsiness) is a common side effect of ZyrTEC-D due to the antihistamine component. Although the formulation is generally considered less sedating than some older medications, it is important to recognize this potential effect. Studies indicate that some users may experience reduced alertness, especially when starting the medication.

Q: What should I avoid when taking ZyrTEC-D?

A: According to official product information, regulatory documents advise that alcohol consumption should be avoided while taking ZyrTEC-D. Alcohol can increase the risk of drowsiness, dizziness, and decreased alertness when combined with this medication. Also, official product information warns against using ZyrTEC-D with other products that contain pseudoephedrine or similar decongestants, or certain MAO inhibitors.

How should ZyrTEC-D be stored and disposed of?

Storage and Disposal of ZyrTEC-D

Zyrtec-D (cetirizine hydrochloride and pseudoephedrine hydrochloride) must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F and 77°F), as required by regulatory labeling. The medicine must be protected from light, high humidity, and excessive heat (above 40°C), and it must not be frozen.

Handling and Safety

Keep the medicine in its original container, tightly closed, and out of the reach and sight of children. Do not use the tablets if the inner safety seal or blister unit is broken.

Disposal

Dispose of unused or expired Zyrtec-D using a drug take-back program. If a program is unavailable, mix the uncrushed tablets with an undesirable substance, seal the mixture in a container, and discard it in household trash. Do not flush the product down the toilet or throw it into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.